Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 5/20 | 0.43 |
| ▸ | JAK3 | P52333 | 4/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.38 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3266110 | 0.83 | JAK2 (0.55) | JAK2JAK3PTK2AHRJAK1 | |
| SCHEMBL3263724 | 0.82 | JAK2 (0.45) | JAK2JAK3PTK2AHRSYK | |
| SCHEMBL3303788 | 0.81 | KCNH2 (0.45) | EGLN2TTKJAK2SYKCTSL | |
| SCHEMBL2145075 | 0.80 | EGLN2 (0.40) | EGLN2JAK2JAK3PTK2AHR | |
| SCHEMBL3299482 | 0.78 | JAK2 (0.48) | JAK2JAK3PTK2AHRJAK1 | |
| SCHEMBL2145028 | 0.78 | EGLN2 (0.65) | EGLN2TTKJAK2JAK3PTK2 | |
| SCHEMBL3308087 | 0.78 | EGLN2 (0.56) | EGLN2TTKJAK2JAK3PTK2 | |
| SCHEMBL3262347 | 0.77 | JAK2 (0.61) | JAK2JAK3PTK2AHRJAK1 | |
| SCHEMBL3303680 | 0.76 | JAK2 (0.49) | JAK2JAK3PTK2AHRJAK1 | |
| SCHEMBL3261713 | 0.76 | JAK1 (0.64) | EGLN2JAK2JAK3PTK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | EGLN2 564/4885TTK 355/4885JAK2 26/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | EGLN2 564/4885TTK 355/4885JAK2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.